CoChat
Sign Up
PreprintCited by 5SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studiesCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Comparative COVID-19 Vaccines Effectiveness in Preventing Infections, Hospitalizations, and Deaths with SARS-CoV-2 BA.5 and Ba.2 Omicron Lineages: A Case-Case and Cohort Study Using Electronic Health Records in Portugal

Open access
Kislaya, Irina, Casaca, Pedro, Borges, Vítor, Sousa, Carlos, Ferreira, Bibiana I., Fonte, Ana, Fernandes, Eugenia, Matias Dias, Carlos, Duarte, Silvia, Almeida, José Pedro, Grenho, Inês, Coelho, Luís, Ferreira, Rita, Pita Ferreira, Patrícia, Borges, Cláudia Medeiros, Isidro, Joana, Pinto, Miguel, Menezes, Luís, Sobral, Daniel, Nunes, Alexandra, Santos, Daniela, Maia Gonçalves, António, Vieira, Luís, Gomes, João Paulo, Leite, Pedro Pinto, Nunes, Baltazar, Machado, Ausenda, Peralta-Santos, André·2022·SSRN Electronic Journal
DOI 10.2139/ssrn.4180482
Open this paper in CoChat — free account

Abstract

Background: In the context of a highly vaccinated population and multiple Omicron lineages circulation, it is relevant to clarify the effect of vaccination and previous infections on the risk of infection and severe post-infection outcomes. This study aimed to measure the comparative vaccine effectiveness of primary and booster vaccination between Omicron BA.5 and BA.2 lineages against infection and compare lineage-specific post-infection vaccine effectiveness against COVID-19-related hospitalization and mortality. Methods: Using electronic health records and SARS-CoV-2 laboratory surveillance data, we conducted a case-case and a cohort study covering the period of Omicron BA.2/BA.5 lineage replacement in Portugal (April 25 and June 10, 2022). Variant classification was performed through whole-genome sequencing or Spike Gene Target Failure. Findings: From a total of 27,702 samples, 55.5% were classified as BA.2 and the remaining as BA.5. We observed no evidence of reduced vaccine effectiveness from either the primary vaccination (OR=1.07, 95%CI:0.93-1.23) or booster dose (OR=0.96, 95%CI:0.84-1.09) against BA.5 infection compared with BA.2. Higher odds of previous infection were observed in BA.5 cases compared with BA.2 (OR=1.44; 95%CI:1.30-1.60). Among those infected with BA.5, booster post-infection vaccine effectiveness was 77% (95%CI:49-90%) and 88% (95%CI:70-96%) against COVID-19 hospitalization and death, respectively, while among BA.2 cases, booster post-infection vacci…

Overview

Integrity signals

Registry

Crossref · 10.2139/ssrn.4180482

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 28

  1. H Tegally, 2022, Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa, Nat Med
  2. 2022, Epidemiological update: SARS-CoV-2 Omicron sub-lineages BA.4 and BA, 5
  3. 2021, European Centre for Disease Prevention and Control. COVID-19 Vaccine Tracker | European Centre for Disease Prevention and Control, Eur. Cent. Dis. Prev. Control
  4. 2022, European Centre for Disease Prevention and Control, COVID-19 Situation Dashboard
  5. 2022, Genetic diversity of the novel coronavirus SARS-CoV-2 (COVID-19) in Portugal
  6. Q Wang, 2022, Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5, Nature
  7. N P Hachmann, 2022, Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5, N Engl J Med, 387
  8. I Kimura, 2022, Virological characteristics of the novel SARS-CoV-2 Omicron variants including BA.2.12.1, BA.4 and BA.5, bioRxiv
  9. Y Kawaoka, Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 clinical isolates
  10. C H Hansen, 2022, Risk of Reinfection, Vaccine Protection, and Severity of Infection with the BA.5 Omicron Subvariant: A Danish Nation-Wide Population-Based Study
  11. B Meng, 2022, Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity, Nature, 603, 706, 10.1038/s41586-022-04474-x · DOI · Paper page
  12. H N Altarawneh, 2022, Protection of SARS-CoV-2 natural infection against reinfection with the Omicron BA.4 or BA.5 subvariants, medRxiv
  13. Public Health, 2022, SARS-CoV-2 variants of concern and variants under investigation in England
  14. M-A Davies, 2022, Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa. medRxiv
  15. L Cao, 2022, Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance, Nat Med, 1
  16. M E Mcmenamin, 2022, Estimation of Relative Vaccine Effectiveness in Influenza: A Systematic Review of Methodology, Epidemiology, 33, 334, 10.1097/EDE.0000000000001473 · DOI
  17. K Pogreba-Brown, 2020, Methodology minute: An overview of the case-case study design and its applications in infection prevention, Am J Infect Control, 48, 342, 10.1016/j.ajic.2018.11.024 · DOI
  18. M E Halloran, Design and Analysis of Vaccine Studies
  19. B Nunes, 2021, mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, Euro Surveill, 26, 10.2807/1560-7917.ES.2021.26.38.2100833 · DOI
  20. I Kislaya, 2022, Comparative Effectiveness of Coronavirus Vaccine in Preventing Breakthrough Infections among Vaccinated Persons Infected with Delta and Alpha Variants, Emerging Infectious Diseases journal -CDC. Emerg Infect Dis, 28, 331, 10.3201/eid2802.211789 · DOI
  21. A Peralta-Santos, 2022, Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2), medRxiv
  22. 2022, Data on testing for COVID-19 by week and country. Data Test. COVID-19 by week Ctry
  23. C Rao, 2020, Medical certification of cause of death for COVID-19, Bull. World Health Organ, 98
  24. A M Nunes, 2017, Tecnologias de informa��o e comunica��o no registro de �bitos em Portugal, J Heal Informatics, 9, 137
  25. D Firth, 1993, Bias Reduction of Maximum Likelihood Estimates, Biometrika, 80, 27, 10.1093/biomet/80.1.27 · DOI · Paper page
  26. J E Bowen, 2022, Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines, bioRxiv Prepr Serv Biol, 203, 1
  27. I Kislaya, 2021, Seroprevalence of SARS-CoV-2 infection in Portugal in May-July 2020: Results of the first national serological survey (ISNCOVID-19), Acta Med Port, 34, 87, 10.20344/amp.15122 · DOI
  28. I Kislaya, 2022, SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19), Infect Dis (Auckl), 54, 418, 10.1080/23744235.2021.2025421 · DOI

Cited by

Sorted by citations

Metadata

Authors
Kislaya, I., Casaca, P., Borges, V., Sousa, C., Ferreira, B. I., Fonte, A., Fernandes, E., Matias Dias, C., Duarte, S., Almeida, J. P., Grenho, I., Coelho, L., Ferreira, R., Pita Ferreira, P., Borges, C. M., Isidro, J., Pinto, M., Menezes, L., Sobral, D., Nunes, A., Santos, D., Maia Gonçalves, A., Vieira, L., Gomes, J. P., Leite, P. P., Nunes, B., Machado, A., & Peralta-Santos, A.
Affiliations
  • National Institute of Health Dr. Ricardo Jorge (PT)
  • Unilabs (Switzerland) (CH)
  • Algarve Biomedical Center (PT)
  • Administracao Central do Sistema de Saude (PT)
  • Universidade Nova de Lisboa (PT)
Corresponding author
Kislaya, Irina
ORCID
Venue
SSRN Electronic Journal
Publisher
Elsevier BV
Published
2022
ISSN
1556-5068 (ISSN-L)
DOI
10.2139/ssrn.4180482
OpenAlex
W4289824658
Cited by
5
References
1
Citations by year
2024: 1 · 2023: 3 · 2022: 1
Type
posted content
Language
en
Open access
Locations
SSRN Electronic Journal (acceptedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
COVID-19 pandemic, Omicron BA.2, vaccine effectiveness, booster vaccination, prior SARS-CoV-2 infection, COVID-19 hospitalization, COVID-19 mortality, Portugal, whole genome sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review